刘成娟,保善茵,张 曼,李国元

HER-2阳性晚期实体肿瘤的治疗在过去几十年中取得了显著进展，尤其是抗体偶联药物（ADCs）的发展为患者提供了新的治疗选择。抗体偶联药物（ADC）是一种含有抗原特异性抗体和细胞毒性有效载荷的药物，它们将单克隆抗体的准确靶向与细胞毒性化疗药物的疗效相结合，规避了全身毒性，并拥有优于单独靶向药物的致死率。人表皮生长因子受体（HER）家族在调节细胞增殖、存活、分化和迁移中起关键作用。HER2在各种肿瘤中的过表达是HER2阳性癌症中ADC治疗最常见的靶向抗原之一。HER2定向ADC已成为HER2阳性癌症患者有前途的治疗方式。本综述通过总结三种已批准的抗HER2 ADC（T-DM1、DS-8201a和RC48）在晚期实体肿瘤中的应用，总结ADC单药和联合治疗的研究进展，将指导抗HER2治疗的未来应用。

抗体-药物偶联物；人表皮生长因子受体2（HER2）；新型抗HER2 ADC；曲妥珠单抗deruxtecan；曲妥珠单抗emtansine；Disitamab vedotin

[1] WIEDUWILT M J,MOASSER M M.The epidermal growth factor receptor family:biology driving targeted therapeutics[J].Cell Mol Life Sci,2008,65(10):1566-84. [2] BEERLI R R,HYNES N E.Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities[J].J Biol Chem,1996,271(11):6071-6. [3] IYER G,AL-AHMADIE H,SCHULTZ N,et al.Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer[J].J Clin Oncol,2013,31(25):3133-40. [4] STRICKLER J H,YOSHINO T,GRAHAM R P,et al.Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer:A Review[J].JAMA Oncol,2022,8(5):760-9. [5] VAN CUTSEM E,BANG Y J,FENG-YI F,et al.HER2 screening data from ToGA:targeting HER2 in gastric and gastroesophageal junction cancer[J].Gastric Cancer,2015,18(3):476-84. [6] LI B T,ROSS D S,AISNER D L,et al.HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers[J].J Thorac Oncol,2016,11(3):414-9. [7] JIANG J,DONG L,WANG L,et al.HER2-targeted antibody drug conjugates for ovarian cancer therapy[J].Eur J Pharm Sci,2016,93:274-86. [8] IQBAL N,IQBAL N.Human Epidermal Growth Factor Receptor 2(HER2)in Cancers:Overexpression and Therapeutic Implications[J]. Mol Biol Int,2014,2014:852748. [9] ARKHIPOV A,SHAN Y,KIM E T,et al.Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family[J].Elife,2013,2:e00708. [10] ABDOLLAHPOUR-ALITAPPEH M,LOTFINIA M,GHARIBI T,et al.Antibody-drug conjugates(ADCs)for cancer therapy:Strategies, challenges,and successes[J].J Cell Physiol,2019,234(5):5628-42. [11] MONTEMURRO F,DELALOGE S,BARRIOS C H,et al.Trastuzumab emtansine(T-DM1)in patients with HER2-positive metastatic breast cancer and brain metastases:exploratory final analysis of cohort 1 from KAMILLA,a single-arm phase IIIb clinical trial(☆)[J].Ann Oncol,2020,31(10):1350-8. [12] CLARK A S,YAU C,WOLF D M,et al.Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+)breast cancer in the adaptively randomized I-SPY2 trial[J].Nat Commun,2021,12(1):6428. [13] HUANG L,PANG D,YANG H,et al.Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer:final analysis of the randomized phase III PEONY trial[J].Nat Commun,2024,15(1):2153. [14] JENKINS S,ZHANG W,STEINBERG S M,et al.Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases[J].Clin Cancer Res,2023,29(8):1450-9. [15] LA MONICA S,CRETELLA D,BONELLI M,et al.Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines[J].J Exp Clin Cancer Res,2017,36(1):174. [16] OGITANI Y,HAGIHARA K,OITATE M,et al.Bystander killing effect of DS-8201a,a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate,in tumors with human epidermal growth factor receptor 2 heterogeneity[J].Cancer Sci,2016,107(7):1039-46. [17] OGITANI Y,AIDA T,HAGIHARA K,et al.DS-8201a,A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1[J].Clin Cancer Res,2016,22(20):5097-108. [18] KEAM S J.Trastuzumab Deruxtecan:First Approval[J].Drugs,2020,80(5):501-8. [19] MODI S,SAURA C,YAMASHITA T,et al.Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer[J].N Engl J Med,2020,382(7):610-21. [20] ANDRE F,HEE PARK Y,KIM S B,et al.Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer(DESTINY-Breast02):a randomised,open-label,multicentre,phase 3 trial[J].Lancet,2023,401(10390):1773-85. [21] CURIGLIANO G,DUNTON K,ROSENLUND M,et al.Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study[J].Ann Oncol,2023,34(7):569-77. [22] MODI S,JACOT W,YAMASHITA T,et al.Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer[J].N Engl J Med,2022,387(1):9-20. [23] NARAYAN P,DILAWARI A,OSGOOD C,et al.US Food and Drug Administration Approval Summary:Fam-Trastuzumab Deruxtecan- nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer[J].J Clin Oncol,2023,41(11):2108-16. [24] HU S,ZHAO Y,XIE Y,et al.Clinicopathological characteristics,evolution,and treatment outcomes of hormone receptor-negative/HER2- low metastatic breast cancer:a pooled analysis of individual patient data from three prospective clinical trials[J].Front Endocrinol (Lausanne),2024,15:1449278. [25] VAZ BATISTA M,PEREZ-GARCIA J M,CORTEZ P,et al.Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases:the DEBBRAH trial[J].ESMO Open,2024,9(9):103699. [26] FABI A,ROSSI A,CAPUTO R,et al.Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan [J].NPJ Precis Oncol,2025,9(1):22. [27] GOUDA M A,GONUGUNTA A,DUMBRAVA E E,et al.Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer[J].Clin Cancer Res,2025. [28] JOHNSTON L E,RANDALL J,CHOURAICHI S,et al.Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer[J].NPJ Precis Oncol,2024,8(1):203. [29] ZENG J,MA W,YOUNG R B,et al.Targeting HER2 genomic alterations in non-small cell lung cancer[J].J Natl Cancer Cent,2021,1(2):58-73. [30] JIANG J,LI S,SHAN X,et al.Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE[J]. Toxicol Lett,2020,324:30-7. [31] XU Y,WANG Y,GONG J,et al.Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48- ADC in patients with HER2-positive advanced solid tumors[J].Gastric Cancer,2021,24(4):913-25. [32] PENG Z,LIU T,WEI J,et al.Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2- overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study[J].Cancer Commun(Lond),2021,41(11):1173-82. [33] NIE C,XU W,GUO Y,et al.Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer:a multicenter real-world study[J].BMC Cancer,2023,23(1):1239. [34] ALAMEDDINE R,MALLEA P,SHAHAB F,et al.Antibody Drug Conjugates in Bladder Cancer:Current Milestones and Future Perspectives[J].Curr Treat Options Oncol,2023,24(9):1167-82. [35] YU J,WU S,LI R,et al.Novel ADCs and combination therapy in urothelial carcinoma:latest updates from the 2023 ASCO-GU Cancers Symposium[J].J Hematol Oncol,2023,16(1):85. [36] SHENG X,YAN X,WANG L,et al.Open-label,Multicenter,Phase II Study of RC48-ADC,a HER2-Targeting Antibody-Drug Conjugate,in Patients with Locally Advanced or Metastatic Urothelial Carcinoma[J].Clin Cancer Res,2021,27(1):43-51. [37] SHI F,LIU Y,ZHOU X,et al.Disitamab vedotin:a novel antibody-drug conjugates for cancer therapy[J].Drug Deliv,2022,29(1):1335-44. [38] SHENG X,WANG L,HE Z,et al.Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma:A Combined Analysis of Two Phase II Clinical Trials[J].J Clin Oncol, 2024,42(12):1391-402. [39] CHEN M,YAO K,CAO M,et al.HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma:a multicenter,real-world study[J].Cancer Immunol Immunother,2023,72(7):2309-18. [40] WEI Y,ZHANG R,YU C,et al.Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma:a two-center's real-world study[J].Front Pharmacol,2023,14:1230395.

点击下载PDF